Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 169

1.

Structural damage in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future.

Schett G, Coates LC, Ash ZR, Finzel S, Conaghan PG.

Arthritis Res Ther. 2011 May 25;13 Suppl 1:S4. doi: 10.1186/1478-6354-13-S1-S4. Review.

2.

Anti-TNF therapy: what have we learned in 12 years?

Kalden JR.

Arthritis Res Ther. 2011 May 25;13 Suppl 1:S1. doi: 10.1186/1478-6354-13-S1-S1. No abstract available.

3.

Golimumab: a new anti-TNF-alpha agent for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.

Voulgari PV.

Expert Rev Clin Immunol. 2010 Sep;6(5):721-33. doi: 10.1586/eci.10.49. Review.

PMID:
20828280
4.
6.

Observational study of switching anti-TNF agents in ankylosing spondylitis and psoriatic arthritis versus rheumatoid arthritis.

Haberhauer G, Strehblow C, Fasching P.

Wien Med Wochenschr. 2010 May;160(9-10):220-4. doi: 10.1007/s10354-010-0795-0.

PMID:
20632149
7.

"Are there any evidences for using the intra-articular TNF-α blockade in resistant arthritis?".

Fiocco U, Punzi L.

Joint Bone Spine. 2011 Jul;78(4):331-4. doi: 10.1016/j.jbspin.2011.01.005. Epub 2011 Feb 25. No abstract available.

PMID:
21353617
8.

Biologics in the treatment of rheumatoid arthritis and ankylosing spondylitis.

Braun J, Kalden JR.

Clin Exp Rheumatol. 2009 Jul-Aug;27(4 Suppl 55):S164-7.

PMID:
19822066
9.

A systematic comparison of rheumatoid arthritis and ankylosing spondylitis: structural outcomes.

Landewé R, van der Heijde D.

Clin Exp Rheumatol. 2009 Jul-Aug;27(4 Suppl 55):S102-7.

PMID:
19822054
10.

Update on anti-tumor necrosis factor therapy in the spondyloarthropathies including psoriatic arthritis.

Kavanaugh A, Tutuncu Z, Catalan-Sanchez T.

Curr Opin Rheumatol. 2006 Jul;18(4):347-53. Review.

PMID:
16763453
11.

Identification of cutpoints for acceptable health status and important improvement in patient-reported outcomes, in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.

Kvamme MK, Kristiansen IS, Lie E, Kvien TK.

J Rheumatol. 2010 Jan;37(1):26-31. doi: 10.3899/jrheum.090449. Epub 2009 Dec 1.

PMID:
19955045
12.

Golimumab: A novel anti-TNF-alpha human monoclonal antibody for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.

Campas-Moya C.

Drugs Today (Barc). 2010 Jan;46(1):13-22. doi: 10.1358/dot.2010.46.1.1444434. Review.

PMID:
20200692
13.

Serum COMP-C3b complexes in rheumatic diseases and relation to anti-TNF-α treatment.

Happonen KE, Saxne T, Geborek P, Andersson M, Bengtsson AA, Hesselstrand R, Heinegård D, Blom AM.

Arthritis Res Ther. 2012 Jan 20;14(1):R15. doi: 10.1186/ar3694.

14.

Infliximab: 12 years of experience.

Smolen JS, Emery P.

Arthritis Res Ther. 2011 May 25;13 Suppl 1:S2. doi: 10.1186/1478-6354-13-S1-S2. Review.

15.

Infliximab treatment of rheumatoid arthritis.

Maini SR.

Rheum Dis Clin North Am. 2004 May;30(2):329-47, vii. Review.

PMID:
15172044
16.

TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis.

Tobin AM, Kirby B.

BioDrugs. 2005;19(1):47-57. Review.

PMID:
15691217
17.

Infliximab inhibits bone resorption by circulating osteoclast precursor cells in patients with rheumatoid arthritis and ankylosing spondylitis.

Gengenbacher M, Sebald HJ, Villiger PM, Hofstetter W, Seitz M.

Ann Rheum Dis. 2008 May;67(5):620-4. Epub 2007 Aug 24.

PMID:
17720725
18.

The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions.

Sfikakis PP.

Curr Dir Autoimmun. 2010;11:180-210. doi: 10.1159/000289205. Epub 2010 Feb 18. Review.

PMID:
20173395
19.

The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients.

Seitz M, Wirthmüller U, Möller B, Villiger PM.

Rheumatology (Oxford). 2007 Jan;46(1):93-6. Epub 2006 May 23.

PMID:
16720636
20.

[RETROSPECTIVE DATA ANALYSIS OF THE PATIENTS WITH INFLAMMATORY JOINT DISEASES TREATED WITH GOLIMUMAB IN CROATIA].

Anić B, Babić-Naglić Ð, Grazio S, Kehler T, Kaliterna DM, Radoncić KM, Morović-Vergles J, Novak S, Prus V, Vlak T, Baresić M.

Reumatizam. 2015;62(1):12-9. Croatian.

PMID:
27024887

Supplemental Content

Support Center